Ipsen: expects net sales of E3.2bn in 2022

(CercleFinance.com) - Prior to an investor day, to be held today, Ipsen has said that by 2022 it aims to report consolidated net sales of about 3.
2 billion euros, with an operating margin of over 32%.

The laboratory states that these forecasts include its existing commercial portfolio of products with currently approved indications and takes into account the impact of the approval and launch of palovarotene for FOP indications only.

"Ipsen currently has five new chemical entities in clinical development, nine significant regulatory submissions planned from 2019 to 2022 and several mid-to-late-stage program readouts in the coming months," said Ipsen's CEO David Meek.


Copyright (c) 2019 CercleFinance.com. All rights reserved.